Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 237

Results For "CE"

9352 News Found

MPP signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of HIV prevention medicine
News | March 30, 2023

MPP signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of HIV prevention medicine

Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers


Granules India receives ANDA approval for Gabapentin Tablets
Drug Approval | March 30, 2023

Granules India receives ANDA approval for Gabapentin Tablets

Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults


Sanofi receives marketing approval for its diabetes drug Soliqua in India
Drug Approval | March 29, 2023

Sanofi receives marketing approval for its diabetes drug Soliqua in India

Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing


Zydus receives final approval from USFDA for Loperamide Hydrochloride Capsules
Drug Approval | March 29, 2023

Zydus receives final approval from USFDA for Loperamide Hydrochloride Capsules

Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States


Thalassemics India celebrates 35 years of service in Thalassemia
News | March 29, 2023

Thalassemics India celebrates 35 years of service in Thalassemia

The event witnessed a historic journey of Thalassemics India gracing the theme “LAKSH”


Thermo Fisher Scientific opens cell therapy facility at University of California
News | March 28, 2023

Thermo Fisher Scientific opens cell therapy facility at University of California

The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.


Lupin receives tentative approval from USFDA for Valbenazine capsules
Drug Approval | March 28, 2023

Lupin receives tentative approval from USFDA for Valbenazine capsules

Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).


Lupin announces completion of pharmacovigilance inspection by USFDA
Drug Approval | March 27, 2023

Lupin announces completion of pharmacovigilance inspection by USFDA

The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide


Lupin announces successful completion of UK MHRA inspection of Pithampur facilities
Drug Approval | March 27, 2023

Lupin announces successful completion of UK MHRA inspection of Pithampur facilities

With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility of the company


Briefs: Morepen Laboratories and Zydus Lifesciences
Drug Approval | March 27, 2023

Briefs: Morepen Laboratories and Zydus Lifesciences

The company is addressing these observations